Introduction
============

Allantoin is the primary active compound in yams (Dioscorea spp.) ([@ref-29]). In the pharmaceutical industry, yams are widely used to prevent inflammation and ulcers because they contain ureides such as allantoin ([@ref-17]). Dioscoreaceae plants have also been shown to improve metabolic and diabetic disorders ([@ref-4]; [@ref-30]; [@ref-35]).

Several pathogenic processes are involved in the development of diabetes, including the destruction of pancreatic *β*-cells that results in insulin resistance ([@ref-9]). Autoimmunity is one of the main causes of diabetes type 1 via damage of the insulin-producing *β*-cells in the pancreas ([@ref-1]). In addition to insulin resistance, increased apoptosis and a significant reduction in the number of *β*-cells have been implicated in type 2 diabetes ([@ref-2]). Thus, prevention of pancreatic damage and the development of therapeutic strategies to protect *β*-cells have been introduced as a major target for the management of diabetes ([@ref-24]).

The imidazoline receptor is an orphan receptor with three subtypes. The imidazoline 1 (I1) receptors act to lower blood pressure ([@ref-12]), whereas the imidazoline 2 (I2) receptors serve as an allosteric binding site for monoamine oxidase and are known to be involved in pain modulation, neuroprotection and increased glucose uptake in muscle cells ([@ref-19]; [@ref-22]). The imidazoline 3 (I3) receptors play an important role in regulating insulin secretion from *β*-cells in the pancreas ([@ref-13]).

Guanidine derivates can bind to the imidazoline receptors ([@ref-10]). Allantoin, a guanidine derivative, has been shown to activate the I1 receptors to attenuate hyperlipidemia, improve hepatic steatosis and act as an antihypertensive agent ([@ref-5]; [@ref-36]). Additionally, allantoin also increases glucose uptake in muscle cells via the I2 receptors ([@ref-7]; [@ref-20]). A recent study demonstrated that allantoin was able to bind to the I3 receptors, resulting in the lowering of blood glucose due to increased plasma insulin levels ([@ref-33]). Moreover, insulinotropic agents such as glucagon-like peptide-1, an incretin derived from the transcription product of the proglucagon gene, can also protect *β*-cells from apoptosis ([@ref-3]; [@ref-21]). Thus, we speculated that allantoin may play a role in pancreatic *β*-cell protection via the I3 receptor. The present study aimed to identify the role of allantoin in improving damage in pancreatic *β*-cells induced by a low dose of streptozotocin (STZ).

Material and Methods
====================

Animals
-------

Male Wistar rats weighing 320--340 g obtained from Japan SLC, Inc (Shizuoka, Japan), were maintained in an environment under a 12 h light/12 h dark cycle with a controlled room temperature at the animal center of Kagoshima University (Kagoshima, Japan). Food and tap water were provided *ad libitum* with free access. All procedures in this study were approved by the Ethics Committee for Animal Care and Use of Kagoshima University (IRB approval number MD14059).

Islet isolation and primary culture
-----------------------------------

Following a previous method ([@ref-31]), pancreatic islets were removed from rat pancreases. The pancreases were incised into smaller portions and digested with 1 mg/mL collagenase (Roche, Basel, Switzerland) for 10 min. The digested samples were washed two times with RPMI 1640 medium (Sigma, St. Louis, Missouri, USA) containing 10% fetal bovine serum FBS (Thermo, Waltham, Massachusetts, USA) to inactivate the collagenase. The isolated pancreatic islets were cultured in RPMI 1640 supplemented with 1% penicillin and streptomycin (Life Technology, Carlsbad, California, USA), 1% amphotericin B (Sigma, St. Louis, Missouri, USA) and 10% FBS. The primary culture was incubated (37 °C with 5% CO~2~) for 48 h. After the incubation period, the primary culture was divided into 6-well plates for Live/Dead double staining assay, 96-well plates for the ApoTox-Glo Triplex assay, and 12-well plates for annexin and flow cytometry analysis.

Treatment of cells with reagents
--------------------------------

The primary cultured cells were devided into 6-well plates. The medium was removed, and the cells were washed once with phosphate-buffered saline (PBS). RPMI 1640 medium containing 25 mM glucose was added to each well with 5 mM STZ (Sigma-Aldrich, St. Louis, Missouri, USA) and incubated for 6 h to induce cell apoptosis. To know the role of allantoin in the protection of pancreatic *β*-cells against STZ, allantoin (Sigma-Aldrich, St. Louis, Missouri, USA) pretreatment at various doses was provided before 30 min prior to the addition of 5 mM STZ and incubated for 6 h. To identify the signaling pathway of allantoin in *β*-cells, 1 µM KU14R (Santa Cruz Biotechnology, Santa Cruz, California, USA): an I3 binding site antagonist, or 1 µM U73122 (TOCRIS, Bristol, UK): the phospholipase C (PLC) inhibitor were provided before 30 min prior to the addition of allantoin as previously described before ([@ref-37]). All the medium was removed, and the cells were washed three times with PBS prior to processing for the evaluation of morphology.

Live/dead double staining assay
-------------------------------

Using the Live/dead assay kit (Life Technology, Carlsbad, California, USA), we stained *β*-cells to distinguish the living cells from dead cells according to the manufacturer's instruction. We added 100 µl of Live/Dead solution to the samples and incubated them for 15 min at room temperature. Then, the staining solution was removed and the samples were viewed under a fluorescence microscope (LSM700)(Zeiss, Jena, Germany). Living cells were detected at green fluorescence, whereas dead cells were detected at red fluorescence.

ApoTox-Glo triplex assay
------------------------

The *β*-cells were seeded into 96-well plates at a total density of 1 × 10^4^ cells per well. Each well contained 200 µl RPMI 1640 medium and the test compound where appropriate. ApoTox-Glo Triplex Assay (Promega, Madison, Wisconsin, USA) was used according to the manufacturer's instructions to measure the *β*-cells' viability, cytotoxicity, and apoptosis. After 24 h the Viability/Cytotoxicity reagent, containing both the GF-AFC substrate and the bis-AAF-R110 substrate, was added to all wells and incubated for 30 min. Caspase-Glo 3/7 was added to the wells and mixed briefly for 30 s, then incubated for 30 min at room temperature. Fluorescence was measured at 380EX/510EM to assess viability, 485EX/520EM to assess cytotoxicity, and luminescence was mesured to assess apoptosis.

Annexin V/PI staining and flow cytometry analysis
-------------------------------------------------

The primary cultured *β*-cells were divided into 12-well plates and categorized into four groups. Each group was treated with different reagents as follows: (1) 5 mM STZ; (2) 5 mM STZ and 100 µM allantoin; (3) 5 mM STZ, 1 µM KU14R and 100 µM allantoin; and (4) control. The cells were incubated with the reagents for 48 h. Then, the cells were collected and the apoptotic cells in each group were quantified using Annexin V-PI staining (Life Technology, Carlsbad, California, USA) and analyzed using flow cytometer based on the previously described method ([@ref-23]).

Western blotting analysis
-------------------------

Western blotting analysis was performed to determine caspase-3 and Bcl-2 expression. The *β*-cells were pre-cultured with 5 mM STZ for 6 h prior to the addition of 100 µM allantoin with or without 1 µM KU14R or vehicle for 30 min. The *β*-cells were washed with ice-cold PBS and incubated for 15 min to allow lysis to occur. The protein concentration was measured by BCA protein assay (Thermo Fisher Scientific Inc., Waltham, Massachusetts, USA). The protein samples were filtered and separated by SDS-PAGE (Polyacrylamide Gel Electrophoresis) (10% acrylamide gel) using the Bio-Rad Trans-Blot system and were transferred to polyvinylidene difluoride membranes. The membrane was blocked with 5% non-fat milk in Tris-buffered saline containing 0.1% Tween 20 (TBS-T). The membran was incubated for 2 h and washed with TBS-T and hybridized overnight with primary antibodies, caspase-3 (Merk Millpore, USA) and Bcl-2 (Cell signaling Technology, Danvers, Massachusetts, USA), diluted with a suitable concentration of TBS. Incubation with secondary antibodies and the detection of the antigen-antibody complex was performed using an ECL kit (Thermo Fisher Scientific Inc., Waltham, Massachusetts, USA). The bands densities were quantified using a laser densitometer.

Glucose and insulin levels in STZ-treated rats
----------------------------------------------

The induction of pancreatic cell damage was accomplished by injecting 45 mg/kg STZ dissolved in 10 mM Na-citrated buffer intraperitoneally. STZ-treated rats with blood glucose above 200 mg/dl at 7 days post-injection were included in the group. Total of 24 rats were divided into three groups as follows: Control (STZ) (*n* = 8), STZ + allantoin (*n* = 8), STZ + KU14R + allantoin (*n* = 8). The third group was treated with an intravenous injection of 8 mg/kg/day KU14R; the first and second groups were treated with the same volume of vehicle injected intravenously. After 30 min of KU14R injection, the second and third groups received 10 mg/kg/day of allantoin intravenously. The first group was injected the same volume of vehicle intravenously. The experiments were performed for 8 days. The blood samples were obtained from tail vein everyday. The plasma glucose levels were measured everyday, and the plasma insulin levels were measured on day 0, 4, 6, 8.

Statistical analysis
--------------------

Statistical analyses were performed using SPSS software (SPSS, Inc., Chicago, Illinois, USA). An analysis of variance (ANOVA) with Tukey's test to determine significant differences were used to compare multiple treatment groups. Data are presented as the mean ± standard error (S.E.) based on the number (*n*) of samples in each group. Statistical significance was set at *p* \< 0.05.

Results
=======

Allantoin decreased streptozocin-induced cytotoxicity and apoptosis in *β*-cells
--------------------------------------------------------------------------------

Viable *β*-cells were significantly reduced in the STZ treated group, while cell toxicity and apoptosis were significantly increased compared to the control. In contrast, treatment with allantoin at various concentrations (1 µM, 10 µM, and 100 µM) significantly increased cell viability, and decreased cytotoxicity and apoptosis induced by STZ in a dose-dependent manner. These results suggest that allantoin attenuated STZ-induced cell damage ([Fig. 1](#fig-1){ref-type="fig"}).

![ApoTox-Glo triplex assay showing the viability (A), cytotoxicity (B), and apoptosis (C) of *β*-cells treated with 5 mM streptozotocin (STZ), 5 mM STZ + 1 µM allantoin, 5 mM STZ + 10 µM allantoin, and 5 mM STZ + 100 µM allantoin (*n* = 6 for each group).\
Data are presented as the mean ± SE. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01.](peerj-03-1105-g001){#fig-1}

Allantoin-induced increase in *β*-cell viability was blocked by an I3 antagonist
--------------------------------------------------------------------------------

I3 receptors located on pancreatic *β*-cells are known to stimulate insulin secretion ([@ref-6]; [@ref-10]). Thus, the effect of allantoin on imidazoline I3 receptors was investigated using KU14R, an I3 specific antagonist, in the Apo Tox triplex assay. The effect of allantoin was inhibited by KU14R ([Fig. 2](#fig-2){ref-type="fig"}).

![ApoTox-Glo Triplex assay showing the viability (A), cytotoxicity (B), and apoptosis (C) of *β*-cells in rats treated with 5 mM streptozotocin (STZ), 5 mM STZ + 100 µM allantoin, 5 mM STZ + 1 µM KU14R + 100 µM allantoin (*n* = 6 for each group).\
Data are presented as the mean ± SE. ^∗∗^*P* \< 0.01.](peerj-03-1105-g002){#fig-2}

Allantoin increased the viability of STZ-treated *β*-cells
----------------------------------------------------------

Exposure of the *β*-cells to 5 mM STZ induced apoptosis based on the increase in red fluorescence compared to the control group. The *β*-cell viability was increased by the addition of allantoin, shown by the marked decrease in red fluorescence emitted by EthD-1, which can bind to the DNA of the dead cells. We found that pretreatment with 1 µM KU14R for 30 min resulted in the increased EthD-1 binding, thereby reducing the action of allantoin ([Fig. 3](#fig-3){ref-type="fig"}).

![Cell viability image of *β*-cell after treatment with 5 mM streptozotocin (STZ), 5 mM STZ + 100 µM allantoin, 5 mM STZ + 1 µM KU14R + 100 µM allantoin.\
Allantoin greatly improved the viability of STZ-induced *β*-cells apoptosis.](peerj-03-1105-g003){#fig-3}

Allantoin decreased the *β*-cell apoptosis percentage detected by flow cytometry
--------------------------------------------------------------------------------

Viable cells are located in the lower left quadrant in the flow cytometric analysis. Treatment with 5 mM STZ for 6 h increased the percentage of apoptotic cells to 45.5%, indicated by the increased number of cells in the lower right quadrant. Allantoin reversed this effect and decreased the percentage of apoptotic cells to 32.7%, as shown by movement of the cell population from the lower right quadrant to the lower left quadrant. Co-treatment with KU14R blocked the action of allantoin and induce apoptosis to 53.9% ([Fig. 4](#fig-4){ref-type="fig"}).

![Flow cytometry of apoptotic cells.\
Samples were incubated with FITC-labeled Annexin-V and propidium iodide. Number at the corner represent the percentage of cells found in each quadrant.](peerj-03-1105-g004){#fig-4}

Allantoin-induced cell protective effect involved phospholipase C
-----------------------------------------------------------------

To test whether the protective effect of allantoin involves the PLC pathway, we applied U73122: a PLC inhibitor. U73122 attenuated the protective effect of allantoin in *β*-cells ([Fig. 5](#fig-5){ref-type="fig"}).

![ApoTox-Glo Triplex assay showing the viability (A), cytotoxicity (B), and apoptosis (C) of *β*-cells in rats treated with 5 mM streptozotocin (STZ), 5 mM STZ + 100 µM allantoin, 5 mM STZ + 1 µM U73122 + 100 µM allantoin (*n* = 6 for each group).\
Data are presented as the mean ± SE. ^∗∗^*P* \< 0.01.](peerj-03-1105-g005){#fig-5}

Allantoin decreased caspase-3 and increased Bcl-2 expression
------------------------------------------------------------

Caspase-3 and Bcl-2 are associated with the process of cell death. Caspase-3 is known to play a central role in cell apoptosis, whereas Bcl-2 regulates cell death. We used Western blotting analysis to detect the expression of these two regulatory proteins. In the STZ-treated group, the expression level of caspase-3 was significantly increased, while the Bcl-2 level was significantly decreased. Allantoin significantly suppressed the expression of caspase-3 and significantly increased the expression of Bcl-2. In contrast, KU14R significantly inhibited these actions of allantoin ([Fig. 6](#fig-6){ref-type="fig"}).

![Western blotting analysis of the expression levels of caspase-3 and Bcl-2.\
The expression level of caspase-3 was reduced by allantoin (A), while Bcl2 expression was increased (B) (*n* = 6 for each group). Data are presented as the mean ± SE. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01.](peerj-03-1105-g006){#fig-6}

Plasma glucose levels in rats treated with STZ, allantoin, and KU14R
--------------------------------------------------------------------

Plasma glucose levels were increased following intraperitoneal injection of STZ. Treatment with allantoin significantly lowered the blood glucose levels in STZ-treated rats. This effect of allantoin was countered by combined treatment with KU14R ([Fig. 7](#fig-7){ref-type="fig"}).

![Effects of allantoin and KU14R on blood glucose levels in streptozotocin (STZ) -treated rats.\
STZ-treated rats were daily treated with 10 mg/kg allantoin and 8 mg/kg KU14R. Plasma glucose levels were measured daily for 8 days (*n* = 8 for each group). Values are presented as the mean ± SE. ^∗^*P* \< 0.05 and ^∗∗^*P* \< 0.01 for the difference between STZ and STZ + Allantoin + KU14R. \# \< 0.05 for the difference between STZ + Allatoin and STZ + Allantoin + KU14R.](peerj-03-1105-g007){#fig-7}

Plasma insulin levels in rats treated with STZ, allantoin, and KU14R
--------------------------------------------------------------------

Plasma insulin levels were decreased following intraperitoneal injection of STZ. Treatment with allantoin significantly improved the plasma insulin levels. In contrast, co-treatment with KU14R countered this effect of allantoin ([Fig. 8](#fig-8){ref-type="fig"}).

![Effects of allantoin and KU14R on plasma insulin levels in streptozotocin (STZ) -treated rats.\
STZ-treated rats were daily treated with 10 mg/kg allantoin and 8 mg/kg KU14R. Plasma insulin levels were measured on day 0, 4, 6, 8 (*n* = 8 for each group). Values are presented as the mean ± SE. ^∗∗^*P* \< 0.01 for the difference between STZ and STZ + Allantoin or STZ + Allantoin + KU14R. \# \< 0.05 and \#\# \< 0.01 for the difference between STZ + Allatoin and STZ + Allantoin + KU14R.](peerj-03-1105-g008){#fig-8}

Discussion
==========

Allantoin is known to bind to the imidazoline receptors ([@ref-8]; [@ref-33]). In the present study, we found that allantoin could activate the I3 receptors to protect *β*-cells from the damage induced by STZ.

Diabetic disorders are associated with progressive *β*-cell failure and apoptosis ([@ref-11]). STZ induced diabetes is well-established and accepted in studies of pathogenesis as well as the complication of diabetes ([@ref-32]), and it has been widely used in experimental animals ([@ref-28]) and cytotoxic effect of STZ in *β*-cells ([@ref-18]). To mimic this disorder, we treated *β*-cells with STZ (5 mM) in medium containing 25 mM glucose for 6 h. Moreover, high glucose is known to increase pancreatic cell vulnerability to toxic damage by increasing the expression of potential autoantigens on the cell membrane surface ([@ref-25]). Therefore, we established a model that induced significant changes in *β*-cells, including the induction of an apoptotic response.

In the present study, we found that allantoin attenuated the damage induced by STZ in a dose-dependent manner, resulting in the reduction of STZ-induced *β*-cell apoptosis. Allantoin induced a significant decrease in caspase-3 expression and an increase in Bcl-2 expression detected by Western blotting. Caspases activation plays an important role in the execution phase of cell apoptosis ([@ref-14]; [@ref-16]), while Bcl-2 is considered to act as an anti-apoptotic protein that promotes cell survival ([@ref-34]). Thus, allantoin can increase the survival rate of *β*-cells through improvement of apoptosis.

Imidazoline compounds have been suggested to induce insulin secretion from pancreatic *β*-cells through activation of the I3 receptors located on the *β*-cells ([@ref-33]). In the presence of KU14R, I3 receptor antagonist, the protective effect induced by allantoin in *β*-cells was partially blocked. Flow cytometric analysis also supported this findings. As shown in [Fig. 4](#fig-4){ref-type="fig"}, cell viabilities were improved after allantoin treatment, and this effect was also suppressed by the blockade of I3 receptors using KU14R. As previously described, rats injected with a low dose of STZ exhibited higher blood glucose and lower plasma insulin levels ([@ref-33]). Allantoin improved the damaged function of *β*-cells in this animal model, which resulted in an increase of plasma insulin levels and a reduction of plasma glucose levels. This *in vivo* action of allantoin was also inhibited by KU14R to block the I3 receptors. Thus, the action of allantoin via the activation of I3 receptors was shown both *in vivo* and *in vitro*. Similar result was also observed in the action of canavanine ([@ref-37]).

Moreover, we found that the protective effect of allantoin was linked to the phospholipase C (PLC) pathway. In the presence of U73122, a well-known PLC inhibitor, the protective effect of allantoin was markedly reduced ([Fig. 5](#fig-5){ref-type="fig"}). In theory, upon activation, PLC cleaves phosphatidylinositol 4,5-biphosphate into diacylglycerol and inositol 1,4,5-triphosphate, which may potentiate insulin secretion ([@ref-15]). Whether this action is related to the protection of *β*-cells shall be investigated in future studies.

Additionally, several yam species (Dioscorea spp.) are also known to contain saponin and the aglycone portion of saponin called sapogenin, that are also proven to be beneficial in STZ induced diabetic rats ([@ref-26]; [@ref-27]). Taken together, allantoin or yam (Dioscorea spp.) seems beneficial to treat and/or prevent the diabetes in the future.

Nevertheless, for the first time, we characterized the improvement of STZ-induced *β*-cell damage by allantoin via the I3 receptors both *in vivo* and *in vitro*.

Conclusion
==========

Allantoin has the ability to increase *β*-cells viability and ameliorate *β*-cell damage through activation of the I3 receptors. Thus, allantoin and related analogs supplied as nutrients may be useful for the improvement of early stage of *β*-cell damage.
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